Eversept Partners
Latest statistics and disclosures from Eversept Partners's latest quarterly 13F-HR filing:
- Top 5 stock holdings are AMRN, UTHR, ALXN, TGTX, AZN, and represent 34.97% of Eversept Partners's stock portfolio.
- Added to shares of these 10 stocks: ALXN (+$59M), AZN (+$40M), UTHR (+$33M), GSK (+$33M), NVST (+$29M), AVTR (+$26M), AMRN (+$26M), SRPT (+$23M), ANTM (+$21M), DHR (+$21M).
- Started 23 new stock positions in MCRB, SRDX, A, ALXN, FPRX, KDMN, AVTR, ALT, NVST, AUTL. MRUS, ZYME, Glaxosmithkline, ANTM, ANAB, DXCM, RAD, MGLN, XGN, IQV, ONCT, CYH, CATB.
- Reduced shares in these 10 stocks: BHVN (-$19M), FATE (-$12M), HSKA (-$12M), , , DCPH (-$8.9M), TGTX (-$8.3M), ENSG (-$8.1M), AMRX (-$6.8M), MODN (-$6.7M).
- Sold out of its positions in CLDX, FLDM, LQDA, MRSN, MODN, Momenta Pharmaceuticals, OSUR, SCPH, SLDB, TLGT. Mylan Nv.
- Eversept Partners was a net buyer of stock by $276M.
- Eversept Partners has $841M in assets under management (AUM), dropping by 89.04%.
Tip: Access up to 7 years of quarterly data
Positions held by Eversept Partners, LLC consolidated in one spreadsheet with up to 7 years of data
Download as csv

Portfolio Holdings for Eversept Partners
Companies in the Eversept Partners portfolio as of the December 2020 quarterly 13F filing
Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
---|---|---|---|---|---|---|
Amarin Corp Spons Adr New (AMRN) | 9.3 | $78M | +49% | 16M | 4.89 | |
United Therapeutics Corporation (UTHR) | 8.3 | $70M | +90% | 459k | 151.79 | |
Alexion Pharmaceuticals (ALXN) | 7.0 | $59M | NEW | 376k | 156.24 | |
Tg Therapeutics (TGTX) | 5.3 | $45M | -15% | 864k | 52.02 | |
Astrazeneca Sponsored Adr (AZN) | 5.1 | $43M | +1298% | 852k | 49.99 | |
Horizon Therapeutics Pub L SHS (HZNP) | 4.6 | $39M | -12% | 531k | 73.15 | |
Fate Therapeutics (FATE) | 4.3 | $36M | -25% | 400k | 90.93 | |
Glaxosmithkline Sponsored Adr (GSK) | 4.2 | $35M | +1370% | 947k | 37.18 | |
Ascendis Pharma A/s Sponsored Adr (ASND) | 3.7 | $31M | +16% | 187k | 166.78 | |
Catalent (CTLT) | 3.5 | $29M | +99% | 280k | 104.07 | |
Envista Hldgs Corp (NVST) | 3.5 | $29M | NEW | 861k | 33.73 | |
Danaher Corporation (DHR) | 3.3 | $28M | +302% | 126k | 222.29 | |
Teva Pharmaceutical Inds Sponsored Ads (TEVA) | 3.2 | $27M | +14% | 2.7M | 9.65 | |
Avantor (AVTR) | 3.1 | $26M | NEW | 921k | 28.15 | |
Setup an alertEversept Partners will file the next quarterly 13-HR in about 3 months. Would you like to be notified? |
||||||
Sarepta Therapeutics (SRPT) | 2.8 | $24M | +7208% | 139k | 170.49 | |
Anthem (ANTM) | 2.5 | $21M | NEW | 66k | 321.08 | |
Zogenix Com New (ZGNX) | 2.2 | $18M | +5% | 910k | 19.99 | |
Qiagen Nv Shs New (QGEN) | 2.1 | $18M | +101% | 337k | 52.85 | |
Ensign (ENSG) | 1.8 | $15M | -34% | 209k | 72.98 | |
Deciphera Pharmaceuticals (DCPH) | 1.7 | $14M | -38% | 246k | 57.07 | |
Intra Cellular Therapies (ITCI) | 1.3 | $11M | +101% | 356k | 31.80 | |
Taro Pharmaceutical Inds SHS (TARO) | 1.3 | $11M | +7% | 152k | 73.42 | |
Heska Corp Com Restrc New (HSKA) | 1.3 | $11M | -52% | 76k | 145.66 | |
Kadmon Hldgs (KDMN) | 1.2 | $10M | NEW | 2.4M | 4.15 | |
Biohaven Pharmaceutical Holding (BHVN) | 1.1 | $8.9M | -67% | 104k | 85.71 | |
Magellan Health Com New (MGLN) | 1.0 | $8.7M | NEW | 105k | 82.84 | |
Rite Aid Corporation (RAD) | 1.0 | $8.4M | NEW | 532k | 15.83 | |
Aurinia Pharmaceuticals (AUPH) | 1.0 | $8.4M | +38% | 604k | 13.83 | |
Seres Therapeutics (MCRB) | 1.0 | $8.2M | NEW | 334k | 24.50 | |
Glaxosmithkline Call | 0.9 | $7.4M | NEW | 3.5k | 2089.90 | |
Quidel Corporation (QDEL) | 0.9 | $7.3M | +334% | 41k | 179.66 | |
Affimed Therapeutics B V (AFMD) | 0.7 | $5.6M | -22% | 965k | 5.82 | |
Amneal Pharmaceuticals Com Stk Cl A (AMRX) | 0.6 | $5.4M | -55% | 1.2M | 4.57 | |
Oxford Immunotec Global Ord Shs (OXFD) | 0.6 | $5.4M | +4% | 308k | 17.47 | |
Altimmune Com New (ALT) | 0.5 | $4.3M | NEW | 380k | 11.28 | |
BioCryst Pharmaceuticals (BCRX) | 0.4 | $3.7M | -56% | 492k | 7.45 | |
Five Prime Therapeutics (FPRX) | 0.4 | $3.6M | NEW | 209k | 17.01 | |
Sanofi Sponsored Adr (SNY) | 0.4 | $3.3M | +36% | 68k | 48.59 | |
Hca Holdings (HCA) | 0.3 | $2.8M | -68% | 17k | 164.44 | |
Prothena Corp SHS (PRTA) | 0.3 | $2.4M | +3% | 203k | 12.01 | |
Sesen Bio (SESN) | 0.3 | $2.1M | 1.6M | 1.35 | ||
Anaptysbio Inc Common (ANAB) | 0.2 | $1.9M | NEW | 88k | 21.50 | |
SurModics (SRDX) | 0.2 | $1.8M | NEW | 41k | 43.51 | |
Oncternal Therapeutics (ONCT) | 0.2 | $1.7M | NEW | 344k | 4.90 | |
Otonomy (OTIC) | 0.2 | $1.6M | -38% | 253k | 6.47 | |
Autolus Therapeutics Spon Ads (AUTL) | 0.2 | $1.4M | NEW | 155k | 8.94 | |
Concert Pharmaceuticals I equity (CNCE) | 0.2 | $1.3M | 104k | 12.64 | ||
Catabasis Pharmaceuticals In Com New (CATB) | 0.1 | $1.1M | NEW | 522k | 2.14 | |
Exagen (XGN) | 0.1 | $1.1M | NEW | 82k | 13.20 | |
Dex (DXCM) | 0.1 | $914k | NEW | 2.5k | 369.59 | |
Protara Therapeutics Com Stk (TARA) | 0.1 | $879k | 36k | 24.21 | ||
Iqvia Holdings (IQV) | 0.1 | $732k | NEW | 4.1k | 179.19 | |
Agilent Technologies Inc C ommon (A) | 0.1 | $590k | NEW | 5.0k | 118.55 | |
Amarin Corp Call | 0.1 | $471k | 13k | 36.64 | ||
Gohealth Com Cl A (GOCO) | 0.0 | $405k | +126% | 30k | 13.64 | |
Kalvista Pharmaceuticals (KALV) | 0.0 | $359k | -82% | 19k | 18.97 | |
Zymeworks (ZYME) | 0.0 | $255k | NEW | 5.4k | 47.18 | |
Merus N V (MRUS) | 0.0 | $253k | NEW | 14k | 17.51 | |
Apellis Pharmaceuticals (APLS) | 0.0 | $218k | -95% | 3.8k | 57.13 | |
Community Health Systems (CYH) | 0.0 | $95k | NEW | 13k | 7.42 |
Past Filings by Eversept Partners
SEC 13F filings are viewable for Eversept Partners going back to 2017
- Eversept Partners 2020 Q4 filed Feb. 16, 2021
- Eversept Partners 2020 Q3 restated filed Nov. 13, 2020
- Eversept Partners 2020 Q3 filed Nov. 12, 2020
- Eversept Partners 2020 Q2 filed Aug. 13, 2020
- Eversept Partners 2020 Q1 filed May 13, 2020
- Eversept Partners 2019 Q4 filed Feb. 13, 2020
- Eversept Partners 2019 Q3 filed Nov. 13, 2019
- Eversept Partners 2019 Q2 restated filed Oct. 30, 2019
- Eversept Partners 2019 Q2 filed Aug. 13, 2019
- Eversept Partners 2019 Q1 filed May 14, 2019
- Eversept Partners 2018 Q4 filed Feb. 13, 2019
- Eversept Partners 2018 Q3 filed Nov. 14, 2018
- Eversept Partners 2018 Q2 filed Aug. 14, 2018
- Eversept Partners 2018 Q1 filed May 14, 2018
- Eversept Partners 2017 Q4 restated filed Feb. 13, 2018
- Eversept Partners 2017 Q4 filed Feb. 12, 2018